BioTuesdays

Tag - H.C. Wainwright

BioCardia

HCW starts BioCardia at buy; PT $9

H.C Wainwright initiated coverage of BioCardia (NASDAQ:BCDA) with a “buy” rating and price target of $9. The stock closed at $1.71 on Dec. 17. BioCardia is a clinical-stage company focused on the development of cell...

89bio

HCW starts 89bio at buy; PT $46

H.C. Wainwright launched coverage of 89bio (NADAQ:ETNB) with a “buy” rating and price target of $46. The stock closed at $11.48 on Dec. 17. 89bio is a clinical-stage biopharmaceutical company focused on the development...

Vor Logo

HCW starts Vor Biopharma at buy; PT $26

H.C. Wainwright initiated coverage of Vor Biopharma (NASDAQ:VOR) with a “buy” rating and $26 price target. The stock closed at $12.13 on Dec. 16. Vor is a clinical-stage cell therapy company focused on developing...

Virios Therapeutics

HCW starts Virios Therapeutics at buy; PT $12

H.C. Wainwright initiated coverage of Virios Therapeutics (NASDAQ:VIRI) with a “buy” rating and price target of $12. The stock closed at $4.58 on Dec. 14. Virios is a clinical-stage biotech company developing a novel...

Gemini Therapeutics

HCW starts Gemini Therapeutics at buy; PT $20

H.C. Wainwright launched coverage of Gemini Therapeutics (NASDAQ:GMTX) with a “buy” rating and $20 price target. The stock closed at $2.43 on Dec. 14. Gemini is developing precision medicines for the treatment of...

Delcath-Systems-Inc

HCW starts Delcath Systems at buy; PT $25

H.C. Wainwright initiated coverage of Delcath Systems (NASDAQ:DCTH) with a “buy” rating and 12-month price target of $25. The stock closed at $8.02 on Dec. 9. Delcath is a clinical-stage interventional oncology company...

Foghorn Therapeutics

HCW starts Foghorn Therapeutics at buy; PT $25

H.C. Wainwright initiated coverage of Foghorn Therapeutics (NASDAQ:FHTX) with a “buy” rating and price target of $25. The stock closed at $13.68 on Nov. 19. Foghorn is a leader in the field of chromatin biology. The...

PharmaCyte Logo

HCW starts PharmaCyte Biotech at neutral

H.C. Wainwright initiated coverage of PharmaCyte Biotech (NASDAQ:PMCB) with a “neutral” rating without a price target, as “we await the FDA’s clinical hold to be lifted.” The stock closed at $2.93 on Oct. 5. “Once...